Tag: Biolexis

 Biolexis Therapeutics Inc., a leader in bio-tech research and creator of the FIELDS™ process, today announced that data highlighting an orally available, CDK9 selective small molecule inhibitor showing promise in n-Myc-driven neuroendocrine prostate cancers (NEPC) was presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2022, which is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans from April 8-13, 2022. Dr. Vankayalapati said of the data, “We are excited to have found a way to promote degradation in neuroendocrine prostate cancer cells and hope that this will ... Read more